US Bancorp DE Has $1.57 Million Stock Position in Exelixis, Inc. $EXEL

US Bancorp DE reduced its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 16.7% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 35,705 shares of the biotechnology company’s stock after selling 7,176 shares during the period. US Bancorp DE’s holdings in Exelixis were worth $1,574,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Byrne Asset Management LLC raised its holdings in Exelixis by 129.0% during the 2nd quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company’s stock worth $31,000 after buying an additional 400 shares during the period. Family Legacy Financial Solutions LLC acquired a new stake in Exelixis during the 2nd quarter worth approximately $33,000. Hemington Wealth Management raised its holdings in Exelixis by 211.3% during the 1st quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company’s stock worth $28,000 after buying an additional 522 shares during the period. Bartlett & CO. Wealth Management LLC acquired a new stake in Exelixis during the 1st quarter worth approximately $37,000. Finally, Steph & Co. acquired a new stake in Exelixis during the 2nd quarter worth approximately $44,000. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Exelixis Trading Down 2.0%

Shares of EXEL opened at $39.21 on Friday. The company has a market cap of $10.56 billion, a price-to-earnings ratio of 18.85, a PEG ratio of 0.80 and a beta of 0.38. Exelixis, Inc. has a 1-year low of $27.86 and a 1-year high of $49.62. The company’s fifty day simple moving average is $38.79 and its 200 day simple moving average is $39.98.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.63 by $0.12. The business had revenue of $568.26 million for the quarter, compared to the consensus estimate of $574.36 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The firm’s revenue for the quarter was down 10.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.84 earnings per share. Exelixis has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on EXEL. Weiss Ratings restated a “buy (b)” rating on shares of Exelixis in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Exelixis from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. Guggenheim reiterated a “buy” rating and issued a $45.00 price objective on shares of Exelixis in a report on Tuesday, July 29th. Barclays assumed coverage on shares of Exelixis in a report on Wednesday, September 17th. They issued an “equal weight” rating and a $40.00 price objective on the stock. Finally, Stephens upgraded shares of Exelixis from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $29.00 to $60.00 in a report on Tuesday, June 24th. Fifteen research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $44.42.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.